The Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK announced new measures to streamline, flexibilize, and make clinical trials more transparent. The changes include an amendment to the Medicines for Human Use (Clinical Trials) Regulations 2004, which will be debated in the new year and implemented in early 2026 after a 12-month period. The aim is to eliminate redundancy, speed up approvals, and protect the development of new treatments for the benefit of patients and the National Health Service. The UK government believes that these changes will enhance the country’s reputation as a top destination for innovative clinical research.
Source link
Clinical trials: New UK framework aims to streamline process and improve transparency
